信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

圣诞节后第一个工作日休市 12-24 12:08:24

80.750

+0.050

+0.06%

最高81.100	最低79.800	成交量392.88万
今开80.700	昨收80.700	日振幅1.61%
总市值1,390亿	流通市值1,390亿	总股本17.21亿
成交额3.16亿	换手率0.23%	流通股本17.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":80.75,"timestamp":1766549304005,"preClose":80.7,"halted":0,"volume":3928757,"delay":0,"floatShares":1721000000,"shares":1721000000,"eps":-0.06451467717502878,"marketStatus":"圣诞节后第一个工作日休市","change":0.05,"latestTime":"12-24 12:08:24","open":80.7,"high":81.1,"low":79.8,"amount":315867245,"amplitude":0.016109,"askPrice":80.75,"askSize":90500,"bidPrice":80.55,"bidSize":31000,"shortable":3,"etf":0,"ttmEps":0.7485593189834832,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":7,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":80.7,"openAndCloseTimeList":[[1766539800000,1766548800000]],"volumeRatio":0.8796494170991929,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.417,"impliedVolPercentile":0.0854},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064130708.USD","LU1997244956.HKD","LU1146622755.USD","03692","LU1064131003.USD","09995","LU1997245177.USD","BK1589","BK0188","02509","LU0405327494.USD","BK0012","LU0405327148.USD","LU1781817850.SGD","BK0057","LU2097828474.EUR","01167","603087","BK0060","BK1593","BK1161","LU2495084118.USD","LU2488822045.USD","LU2097828557.USD","BK1574","000661","688428","688062","LU0502904849.HKD","BK0183","688336","BK0239","LU2097828631.EUR","02096","LU2148510915.USD","600276","002755","LU2097828714.EUR","LU1969619763.USD","02142","BK0028","BK0196","LU2580892862.HKD","01530","LU1328615791.USD","06978","688331","01801","LU2097828805.USD","LU1997245094.SGD"],"gpt_icon":0},{"id":"2594288512","title":"信达生物(01801)股东将股票存入香港上海汇丰银行 存仓市值45.98亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594288512","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594288512?lang=zh_cn&edition=full","pubTime":"2025-12-25 08:08","pubTimestamp":1766621293,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，12月24日，信达生物(01801)股东将股票存入香港上海汇丰银行，存仓市值45.98亿港元，占比3.31%。瑞银发布研报称，信达生物旗下六款新产品及信迪利单抗新适应症已被纳入最新版《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》。此外，信达生物已正式纳入恒生指数。瑞银维持其“买入”评级，目标价137.4港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0516423091.SGD","LU2242644610.SGD","BK4585","LU0516422366.SGD","BK4588","BK1589","LU0516422440.USD","HSBA.UK","LU0164880469.USD","BK1610","LU2328871848.SGD","LU0417516738.SGD","HSHD.SI","LU0540923850.HKD","LU2097828474.EUR","LU1267930227.SGD","BK1161","LU2488822045.USD","LU2097828557.USD","LU0516423174.USD","LU0052756011.USD","LU0348735423.USD","LU0516422952.EUR","BK1231","LU0634319403.HKD","LU0149721374.USD","LU0502904849.HKD","HK0000165453.HKD","BK1601","LU2097828631.EUR","BK4207","LU0455707207.USD","LU0310800965.SGD","LU2097828714.EUR","00005","LU1969619763.USD","03143","LU2097828805.USD","BK4521","LU2236285917.USD","LU1481107354.HKD","LU0128525689.USD","BK1583","01801","BK1572","HSBC"],"gpt_icon":0},{"id":"2593477930","title":"国内商保发展和集采优化 创新药产业链持续活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2593477930","media":"金证研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593477930?lang=zh_cn&edition=full","pubTime":"2025-12-24 21:11","pubTimestamp":1766581900,"startTime":"0","endTime":"0","summary":"随着国内商保发展和集采优化，创新药产业链高景气有望延续。当前支持创新药产业发展已成为政策导向，2025年北京、上海、重庆、四川等多地出台相关政策，推动创新药行业高质量发展。近日，2026年医保药品目录和商保药品目录发布，首次在基本医保目录之外增设商保创新药目录。创新药长期产业趋势确定，在国内政策支持以及美联储进入降息周期的背景下，全球创新药研发持续活跃，2026年还有大量BD落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224211713a6ca8bf6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224211713a6ca8bf6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1794554557.SGD","LU0348766576.USD","LU0348767384.USD","01276","LU0417516738.SGD","LU2488822045.USD","LU0634319403.HKD","LU2778985437.USD","LU0348783233.USD","LU1720050803.USD","LU2399975544.HKD","LU0348784397.USD","01877","ONC","06978","IE00B5MMRT66.SGD","09926","IE00BPRC5H50.USD","LU0561508036.HKD","01801","LU0348827113.USD","BK1161","IE00B543WZ88.USD","LU0348735423.USD","LU0540923850.HKD","LU1961090484.USD","BK1574","LU2476274308.USD","LU2476274720.SGD","LU0417516571.SGD","LU0417516902.SGD","LU0348825331.USD"],"gpt_icon":0},{"id":"2593408011","title":"每日卖空追踪 | 信达生物 12月24日卖空量成交45万股，卖空比例为11.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593408011","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593408011?lang=zh_cn&edition=full","pubTime":"2025-12-24 16:30","pubTimestamp":1766565022,"startTime":"0","endTime":"0","summary":"信达生物北京时间12月24日，涨0.06%，卖空量成交45万股，较上一交易日减少60.87%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224163326a4727ef2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224163326a4727ef2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU1969619763.USD","LU2097828631.EUR","LU2097828714.EUR","HK0000165453.HKD","LU2097828805.USD","LU2242644610.SGD","LU0455707207.USD","LU2488822045.USD","BK1161","LU0502904849.HKD","01801","LU2097828557.USD","BK1589","LU2097828474.EUR","LU2328871848.SGD"],"gpt_icon":0},{"id":"2593419285","title":"普华永道徐佳：中国创新药迎分水岭，量质转型呈分化格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2593419285","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593419285?lang=zh_cn&edition=full","pubTime":"2025-12-23 20:54","pubTimestamp":1766494448,"startTime":"0","endTime":"0","summary":"普华永道中国医药医疗行业主管合伙人徐佳博士在接受21世纪经济报道记者专访时指出，中国创新药已进入“量质转型的分水岭阶段”，呈现“头部崛起、中小突围”的分化格局，而非行业全面复苏。当前，随着2025年国家医保药品目录正式披露，支付端对创新药的支持力度","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223205718a46f0791&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223205718a46f0791&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828474.EUR","LU0502904849.HKD","LU2097828714.EUR","BK1574","HK0000165453.HKD","06978","LU2328871848.SGD","01801","BK1583","LU2097828805.USD","LU1969619763.USD","LU2097828631.EUR","LU0455707207.USD","BK1161","LU2242644610.SGD","BK1589","LU2097828557.USD","09969","LU2488822045.USD","01530"],"gpt_icon":0},{"id":"2593841941","title":"信达生物IBI356启动II期临床 适应症为中重度特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2593841941","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593841941?lang=zh_cn&edition=full","pubTime":"2025-12-23 18:03","pubTimestamp":1766484180,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，信达生物制药（苏州）有限公司的一项评估IBI356在中重度特应性皮炎成人参与者中的有效性和安全性的多中心、随机、双盲、平行、安慰剂对照II期临床研究已启动。IBI356为生物制品，适应症为中重度特应性皮炎。特应性皮炎是一种慢性、复发性、炎症性皮肤病，主要症状有皮肤瘙痒、红斑、丘疹等。诊断主要依据典型临床表现及相关检查，如血清IgE检测等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223190257a6c5adcf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223190257a6c5adcf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","BK1583","HK0000165453.HKD","LU2097828631.EUR","LU2328871848.SGD","LU0455707207.USD","LU2488822045.USD","LU2097828557.USD","LU2242644610.SGD","LU2097828714.EUR","LU0502904849.HKD","BK1161","LU2097828805.USD","LU2097828474.EUR","BK1589","LU1969619763.USD"],"gpt_icon":0},{"id":"2593419496","title":"信达生物12月23日主力净流出876.4万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2593419496","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593419496?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:15","pubTimestamp":1766477744,"startTime":"0","endTime":"0","summary":"12月23日, 信达生物股价跌1.34%，报收80.70元，成交金额7.3亿元，换手率0.52%，振幅3.55%，量比0.86。信达生物今日主力资金净流出876.4万元，上一交易日主力净流入2661.7万元。该股近5个交易日上涨0.68%，主力资金累计净流入3169.6万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流出3.4亿元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223161935a46e0603&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223161935a46e0603&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828805.USD","LU2488822045.USD","BK1161","LU0455707207.USD","LU2328871848.SGD","LU2097828631.EUR","LU2097828474.EUR","LU2097828714.EUR","01801","HK0000165453.HKD","LU2242644610.SGD","LU2097828557.USD","BK1589","LU1969619763.USD","BK1583","LU0502904849.HKD"],"gpt_icon":0},{"id":"2593494070","title":"HTI医药2025年12月第三周周报：行业高景气，持续关注创新药械产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2593494070","media":"海通国际","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593494070?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:07","pubTimestamp":1766477237,"startTime":"0","endTime":"0","summary":"2025年12月第三周A股医药板块表现与大盘相当。2025年12月第三周上证综指上涨0.03%，SW医药生物下跌0.1%，涨跌幅在申万一级行业中排名第19位。截至2025年12月19日，医药板块相对于全部A股的溢价水平目前处于正常水平，当前相对溢价率70.1%。2025年12月第三周美股标普医疗保健精选行业+0.6%，同期标普500+0.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223160731a6c4fe72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223160731a6c4fe72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","09939","HK0000500386.USD","01858","BK1515","02269","HK0000252152.HKD","BK1574","01276","02487","LU2543165471.USD","01530","02359","BK1161","09606","06160","06990","HK0000252160.HKD","02615","06078"],"gpt_icon":0},{"id":"2593462419","title":"信达生物宣布IBI3011（抗人白细胞介素1受体辅助蛋白单克隆抗体，IL-1RAP）完成临床I期研究首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2593462419","media":"信达生物制药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593462419?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:32","pubTimestamp":1766475179,"startTime":"0","endTime":"0","summary":"2025年12月10日，美国旧金山和中国苏州——信达生物制药集团，一家致力于研发、生产和销售肿瘤、自免、代谢、眼科等重大疾病领域创新药物的生物制药公司，近日宣布其自主研发的抗人白细胞介素1受体辅助蛋白单克隆抗体在I期临床研究中完成首例受试者给药。人白细胞介素1受体辅助蛋白是IL-1家族的成员。关于IBI3011IBI3011是靶向IL-1RAP的单克隆抗体。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223153442a46dd43f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223153442a46dd43f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2097828474.EUR","LU2097828714.EUR","LU0455707207.USD","HK0000165453.HKD","LU2097828805.USD","BK1589","LU2097828557.USD","LU2242644610.SGD","01801","LU2488822045.USD","LU2328871848.SGD","LU1969619763.USD","BK1583","LU0502904849.HKD","LU2097828631.EUR"],"gpt_icon":0},{"id":"2593045079","title":"信达生物“染蓝”：中国创新药从故事到资产的成人礼","url":"https://stock-news.laohu8.com/highlight/detail?id=2593045079","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593045079?lang=zh_cn&edition=full","pubTime":"2025-12-23 10:33","pubTimestamp":1766457227,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛资本市场对于中国创新药的态度，在过去的几年间经历了剧烈的摇摆。在行业高歌猛进时，biotech往往被描绘为前景无限的未来之星；而当周期下行时，它们又被打上“高风险、不确定性”的标签。恒生指数的选择标准——市场规模、流动性及财务稳定性，直指投资逻辑的核心。这些传统的价值标尺与过往专注于“讲故事”的biotech企业估值体系形成了鲜明对比。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512233599280151.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599280151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01801","LU0455707207.USD","LU2097828557.USD","159992","LU1969619763.USD","LU2242644610.SGD","LU0502904849.HKD","BK1589","LU2328871848.SGD","HK0000165453.HKD","LU2488822045.USD","LU2097828474.EUR","BK1161","BK1583","LU2097828714.EUR","BK1574","LU2097828805.USD","06978","LU2097828631.EUR"],"gpt_icon":0},{"id":"2593456295","title":"智通港股通资金流向统计(T+2)|12月23日","url":"https://stock-news.laohu8.com/highlight/detail?id=2593456295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593456295?lang=zh_cn&edition=full","pubTime":"2025-12-23 07:31","pubTimestamp":1766446262,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月18日,小米集团-W、美团-W、长飞光纤光缆南向资金净流入金额位列市场前三，分别净流入9.04 亿、4.76 亿、3.56 亿盈富基金、中国移动、信达生物南向资金净流出金额位列市场前三，分别净流出-14.20 亿、-12.95 亿、-2.71 亿在净流入比方面，南方恒指ETF、工银南方中国、美的置业以84.61%、75.00%、65.00%位列市场前三。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00107","82318","00006","00003","03121","89988","00388","03167","01258","06869","HEXmain","00857","01810","03990","02800","02318","01093","00363","03868","01952","01117","03143","PNGAY","81810","01186","00941","01686","03690","03328","09899","06098","03145","00386","06160","HMTD.SI","09985","00272","03442","PAImain","03968","01288","02328","02899","ALBmain","HKXCY","03037","00016","01801"],"gpt_icon":1},{"id":"2593463647","title":"医药生物行业跟踪周报：银屑病口服TYK2/IL23双雄并立格局确立 建议关注益方生物 诺诚健华 海思科等","url":"https://stock-news.laohu8.com/highlight/detail?id=2593463647","media":"东吴证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593463647?lang=zh_cn&edition=full","pubTime":"2025-12-23 00:00","pubTimestamp":1766419200,"startTime":"0","endTime":"0","summary":"2025 年12 月18 日，济民可信集团宣布，其申报的2.2 类及2.4 类新药JMX-2005 注射液已获国家药品监督管理局批准开展临床试验。随着武田新一代TYK2 抑制剂Zasocitinib 三期临床阳性顶线数据的出炉，叠加强生口服IL23 受体拮抗剂Icotrokinra 关键三期研究数据的持续兑现，银屑病口服治疗领域TYK2/IL23 双雄并立的格局正式确立。建议关注在TYK2 赛道具备差异化竞争优势的公司：如益方生物、诺诚健华等，以及布局口服IL23 相关领域的公司：如海思科等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223071133a6c31d0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223071133a6c31d0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","03933","BK1574","09926","09969","BK1161","02615","01276"],"gpt_icon":0},{"id":"2593823456","title":"每日卖空追踪 | 信达生物 12月22日卖空量成交54.75万股，卖空比例为5.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593823456","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593823456?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:30","pubTimestamp":1766392225,"startTime":"0","endTime":"0","summary":"信达生物北京时间12月22日，跌1.74%，卖空量成交54.75万股，较上一交易日减少76.74%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163344a4699458&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163344a4699458&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828631.EUR","BK1589","LU1969619763.USD","LU0455707207.USD","LU2097828474.EUR","LU2328871848.SGD","LU2097828805.USD","BK1161","LU2097828714.EUR","HK0000165453.HKD","BK1583","LU2242644610.SGD","LU2097828557.USD","LU0502904849.HKD","LU2488822045.USD","01801"],"gpt_icon":0},{"id":"2593456889","title":"12月，多家药企减肥药临床迎突破性进展！","url":"https://stock-news.laohu8.com/highlight/detail?id=2593456889","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593456889?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:01","pubTimestamp":1766386875,"startTime":"0","endTime":"0","summary":"值得一提的是，在此背景下，众多国内外药企在临床方面正不断迎来突破。12月以来，就有OrsoBio公司、信达生物、硕迪生物等企业已相继宣布新药临床试验取得积极结果。12月12日，信达生物宣布，其自主开发的GCG/GLP-1双受体激动剂玛仕度肽在中国青少年肥胖人群中的Ib期临床研究达到主要终点。总的来说，药企不断迎来的临床突破与申报进展，将推动减肥药物的密集上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222150451a469330c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222150451a469330c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828557.USD","LU2097828631.EUR","LU2097828714.EUR","HK0000165453.HKD","LU2242644610.SGD","LU2488822045.USD","LU2097828474.EUR","LU2328871848.SGD","LU0455707207.USD","LU0502904849.HKD","01801","LU2097828805.USD","BK1161","BK1589","BK1583","LU1969619763.USD"],"gpt_icon":0},{"id":"2593170975","title":"国产新药：十亿美金 BD 大单爆了","url":"https://stock-news.laohu8.com/highlight/detail?id=2593170975","media":"丁香园 Insight 数据库","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593170975?lang=zh_cn&edition=full","pubTime":"2025-12-22 07:50","pubTimestamp":1766361045,"startTime":"0","endTime":"0","summary":"Insight 数据库显示，国内十亿美金级别的交易中，跨国药企作为买方的占比接近五成，贡献了超过一半的交易额。其中，罗氏对中国创新药资产最为青睐，年内共达成了 3 笔大额交易。另外，从单笔金额来看，国内与 MNC 达成的交易有 5 笔超过了 50 亿美元，其中涉及的产品有COPD 新药、心血管 siRNA 疗法、PD1 双抗、ADC 等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222075317a6bec512&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222075317a6bec512&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828714.EUR","01801","LU2097828631.EUR","HK0000165453.HKD","LU2242644610.SGD","LU2328871848.SGD","BK1589","BK1583","LU1969619763.USD","LU2097828557.USD","01093","LU0455707207.USD","LU0502904849.HKD","LU2097828474.EUR","LU2097828805.USD","01530","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2592146391","title":"医药健康行业周报：蚂蚁阿福带动AI医疗流量 医+药+险全链条赋能","url":"https://stock-news.laohu8.com/highlight/detail?id=2592146391","media":"国金证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592146391?lang=zh_cn&edition=full","pubTime":"2025-12-20 00:00","pubTimestamp":1766160000,"startTime":"0","endTime":"0","summary":"投资逻辑本周蚂蚁阿福APP 上市后高流量带动下医疗AI 主题关注度较高。而蚂蚁阿福从AI 工具到AI 朋友全面升级，并上线健康陪伴、健康问答、健康服务三大功能。我们认为蚂蚁阿福是AI 医疗规模化市场与可行商业模式再验证，同时平台流量有望为“医+药+险”全链条赋能。orforglipron 已提交上市申请，获批上市后有望凭依从性优势进一步延长GLP-1 药物使用周期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220193632a6ba7981&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220193632a6ba7981&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","BK1161","LU2242644610.SGD","HK0000165453.HKD","LU1969619763.USD","BK1583","LU0455707207.USD","LU2097828474.EUR","LU2097828557.USD","LU0502904849.HKD","LU2097828805.USD","LU2328871848.SGD","LU2097828714.EUR","LU2097828631.EUR","01801","LU2488822045.USD"],"gpt_icon":0},{"id":"2592162940","title":"智通港股解盘 | 海南自贸港封关意义重大 无人驾驶利好密集催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2592162940","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592162940?lang=zh_cn&edition=full","pubTime":"2025-12-19 20:58","pubTimestamp":1766149121,"startTime":"0","endTime":"0","summary":"海南自由贸易港昨天正式启动全岛封关，8个对外开放口岸及10个“二线口岸”监管设施全部启用。标志着3万多平方公里的海南岛正式成为海关监管特殊区域，中国对外开放迎来具有里程碑意义的标志性举措。回购的H股股份将作为库存股持有，并在完成回购并披露回购结果公告后三年内完成转让或注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02050","601995","BK1191","02431","01801","LU1969619763.USD","01318","LU0819121731.USD","LU2039709279.SGD","LU1880383366.USD","BK1539","LU0593848301.USD","BK1583","BK1589","BK1564","01316","01999","BK1183","09868","09863","02039","03908","LU0348735423.USD","LU0348766576.USD","01880","BK1224","SG9999002463.SGD","LU0417516902.SGD","LU1719994722.HKD","01057","BK1179","BK1500","LU0455707207.USD","LU0181495838.USD","LU0516423091.SGD","LU1794554557.SGD","BK1521","02269","BK1163","06160","LU2328871848.SGD","02498","03759","LU0307460666.USD","LU1580142542.USD","06821","00699","02533"],"gpt_icon":1},{"id":"2592117274","title":"医药行业 | 2025年医保+商保双目录落地，多元支付体系盘活创新药增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2592117274","media":"交银国际","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592117274?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:09","pubTimestamp":1766135394,"startTime":"0","endTime":"0","summary":"我们认为，更多新药进入目录，有助提升临床用药水平以及创新药行业整体研发回报率；同时，商保资金的引入将为创新药支付带来重要增量资金，未来商业健康险有望与基本医保错位发展，为多元化支付体系的建立奠定基础。分析师 | 丁政宁、诸葛乐懿本文节选自交银国际已发布研究报告《医药行业-2025年医保+商保双目录落地，多元支付体系盘活创新药增量空间》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219175310a45f8bfe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219175310a45f8bfe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","LU2328871848.SGD","LU0455707207.USD","BK1161","01801","BK1583","BK1589","LU2097828474.EUR","LU2097828805.USD","LU2242644610.SGD","LU2097828557.USD","LU2488822045.USD","LU0502904849.HKD","LU1969619763.USD","LU2097828714.EUR","BK1574","HK0000165453.HKD","LU2097828631.EUR"],"gpt_icon":0},{"id":"2592206117","title":"信达生物12月19日主力净流入2902.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2592206117","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592206117?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:15","pubTimestamp":1766132154,"startTime":"0","endTime":"0","summary":"12月19日, 信达生物股价涨2.08%，报收83.25元，成交金额10.8亿元，换手率0.76%，振幅4.41%，量比1.17。信达生物今日主力资金净流入2902.7万元，上一交易日主力净流出2141.2万元。该股近5个交易日下跌1.76%，主力资金累计净流出3988.7万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出3.3亿元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219162114a6b6342f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219162114a6b6342f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","LU0455707207.USD","BK1161","01801","BK1583","BK1589","LU2097828474.EUR","LU2097828805.USD","LU2242644610.SGD","LU2097828557.USD","LU2488822045.USD","LU0502904849.HKD","LU1969619763.USD","LU2097828714.EUR","HK0000165453.HKD","LU2097828631.EUR"],"gpt_icon":0},{"id":"2592180935","title":"智通港股早知道 | 国办印发《关于全链条打击涉烟违法活动的意见》 隔夜美股三大股指集体上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2592180935","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592180935?lang=zh_cn&edition=full","pubTime":"2025-12-19 07:27","pubTimestamp":1766100453,"startTime":"0","endTime":"0","summary":"《意见》要求，聚力打击烟草境外制假走私入境。加强与有关国家执法协作，严厉打击境外假冒中国烟草品牌行为，坚决查处流入、流经我国的非法烟草。《意见》要求，高压严打境内涉烟违法活动。由于该计划及相关附属公司之股东有关变更乃该等程序的结果，本集团并无收取任何现金代价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999000327.SGD","LU1880383440.USD","LU1808992512.USD","LU0345776255.USD","LU1993786604.SGD","LU0455707207.USD","BK1179","IE00B0JY6N72.USD","LU1734074674.USD","BK1554","LU0164872284.USD","LU0143863198.USD","LU0821914370.USD","LU0865486749.SGD","LU0196878994.USD","LU0431992006.USD","LU0052750758.USD","LU0072462343.USD","LU0164880469.USD","LU1048588211.SGD","SG9999001903.USD","IE00BPRC5H50.USD","LU0140636845.USD","LU0214875030.USD","BK1209","LU0244354667.USD","06055","LU0359202008.SGD","LU0370786039.SGD","LU0588545904.SGD","LU0823039010.USD","LU1188198961.HKD","LU1961090484.USD","LU0011963245.USD","LU2097828631.EUR","SG9999001689.USD","LU2488822045.USD","LU0589944569.HKD","LU2097828714.EUR","LU0543330483.HKD","LU0307460666.USD","LU0231483743.USD","LU0251144936.SGD","BK1521","LU0577902371.SGD","LU0918141887.USD","LU0054237671.USD","IE00B3M56506.USD","LU0049853897.USD","LU0287142896.SGD","IE00B031HY20.USD","LU0828237510.HKD","LU0345775950.USD","LU1688375341.USD","LU0878005551.USD","LU1064130708.USD","LU1960683339.HKD","LU0348814723.USD","LU0417516738.SGD","LU0029875118.USD","LU0348788117.USD","SG9999002828.SGD","LU0868486357.SGD","LU0463099449.HKD","LU0577902611.USD","LU0856984785.SGD","LU0502904849.HKD","LU1868837722.USD","LU1251922891.USD","LU2242644610.SGD","LU0348805143.USD","LU0348816934.USD","LU0634319403.HKD","UCmain","LU0320764599.SGD","LU2226246903.HKD","LU1242518857.USD","LU0561508036.HKD","LU2125910500.SGD","LU2476274308.USD","LU1242518931.SGD","SG9999002463.SGD","IE00B5MMRT66.SGD","LU0315178854.USD","LU2097828474.EUR","01801","LU0072913022.USD","LU0918141705.HKD","LU1813983027.USD","LU0449509016.USD","LU2476274720.SGD","LU0047713382.USD","LU0314109678.HKD","LU0572944931.SGD","LU1023057109.AUD","LU2778985437.USD","IE0008368742.USD","LU0165289439.USD","LU0211977185.USD","LU0501845795.SGD","LU1807302812.USD","LU0541502299.USD","LU0181495838.USD","LU2152927971.USD","LU1008478684.HKD","BK1119","LU1720050803.USD","LU0819121731.USD","LU0359201612.USD","BK1583","SG9999014674.SGD","IE0032431581.USD","BK1610","LU0708995583.HKD","BK1589","BK1233","LU0577902538.SGD","LU1794554557.SGD","MPNGY","BK1509","LU0823426480.USD","LU0672654166.SGD","LU0819123356.HKD","LU2148510915.USD","LU0048597586.USD","LU0348825331.USD","LU0577902298.EUR","LU0132412106.USD","LU2087589342.USD","LU1226287529.USD","METmain","LU0348735423.USD","BK1148","BK1580","LU1770036033.HKD","LU2039709279.SGD","LU2045819591.USD","LU0143863784.USD","LU0633140727.USD","LU1868837565.USD","LU0509642566.USD","LU1969619763.USD","LU0456827905.SGD","LU0823038988.USD","IE0034224299.USD","LU0348827113.USD","BK1161","LU0594300179.USD","BK1598","LU1105468828.SGD","LU0873338254.USD","CYB","LU0650527681.SGD","LU0106252389.USD","LU0593848301.USD","LU0043850808.USD","LU1048596156.SGD","LU0067412154.USD","LU1102505762.USD","LU0979878070.USD","BK1615","LU2097828557.USD","LU0620787316.HKD","LU0327786744.USD","LU1282648689.USD","LU1770034418.SGD","LU0797268264.HKD","LU0082770016.USD","LU0499858602.USD","LU0823426308.USD","LU1303224171.USD","LU0261950983.USD","LU0164865239.USD","SG9999002562.SGD","LU0082770016.SGD","BK1604","LU1719994722.HKD","LU0228659784.USD","SG9999000459.SGD","LU0359201885.HKD","LU0164939612.USD","LU0540923850.HKD","BK1591","LU2328871848.SGD","LU0823040885.USD","03393","LU0269904917.USD","LU1152091754.HKD","BK1575","LU0499858438.USD","LU0051755006.USD","LU0605514214.HKD","LU0588545490.SGD","LU0823041008.USD","LU0326948709.USD","LU1481107354.HKD","LU0210526637.USD","LU1328277881.USD","IE0008369823.USD","LU1868838027.USD","IE00B29SXG58.USD","HK0000165453.HKD","LU0683595622.HKD","LU0084288322.USD","LU0588545730.USD","LU1831875114.USD","LU0449515922.USD","HGmain","LU0117841782.USD","LU0828238088.HKD","LU1102505929.USD","LU0577902454.USD","LU0320764755.SGD","LU0588546209.SGD","LU0633140560.USD","LU0880133367.SGD","LU0594300419.USD","LU0611395673.USD","IE00BF5LJ272.USD","LU0048580855.USD","LU0456846285.SGD","BK1181","BK1539","LU0700851271.USD","LU2097828805.USD","LU0417516902.SGD","LU1064131003.USD","LU2399975544.HKD","IE00B543WZ88.USD","LU0128522157.USD","HMTD.SI","LU1328615791.USD","LU0173614495.USD","LU1152091168.USD","LU0737861699.HKD","LU1880383366.USD","LU2257852520.SGD","LU0326950275.SGD","LU0039217434.USD","BK1618","CNHmain","LU1675838814.USD","LU0828237940.HKD","LU0541501648.USD","LU0054450605.USD","LU0531971595.HKD","LU1224709979.USD","BK1594","LU1323998911.USD","BK1142","LU0871576103.HKD","LU0149721374.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.1223},{"period":"3month","weight":-0.1504},{"period":"6month","weight":0.044},{"period":"1year","weight":1.2556},{"period":"ytd","weight":1.2063}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0251},{"period":"6month","weight":0.0632},{"period":"1year","weight":0.2846},{"period":"ytd","weight":0.2871}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.056031},{"month":2,"riseRate":0.714286,"avgChangeRate":0.11927},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.021767},{"month":4,"riseRate":0.714286,"avgChangeRate":0.040816},{"month":5,"riseRate":0.428571,"avgChangeRate":0.027398},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.030003}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}